Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has scheduled its second quarter 2025 financial results announcement for July 30, 2025. The company will release its financial results at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET.
Investors and interested parties can participate by registering in advance to obtain local or toll-free phone numbers. The webcast will be accessible through Teva's investor relations website, with a replay available within 24 hours after the call.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 30 luglio 2025. La società pubblicherà i risultati finanziari alle 7:00 a.m. ET, seguiti da una conference call e una diretta webcast alle 8:00 a.m. ET.
Investitori e soggetti interessati possono partecipare registrandosi in anticipo per ottenere numeri telefonici locali o gratuiti. La diretta webcast sarà accessibile tramite il sito web delle relazioni con gli investitori di Teva, con una replica disponibile entro 24 ore dalla chiamata.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 30 de julio de 2025. La compañía publicará sus resultados financieros a las 7:00 a.m. ET, seguido de una llamada conferencia y una transmisión en vivo a las 8:00 a.m. ET.
Los inversores y las partes interesadas pueden participar registrándose previamente para obtener números telefónicos locales o gratuitos. La transmisión estará disponible a través del sitio web de relaciones con inversionistas de Teva, con una repetición accesible dentro de las 24 horas posteriores a la llamada.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)는 2025년 2분기 재무 결과 발표를 2025년 7월 30일로 예정했습니다. 회사는 동부시간 기준 오전 7시에 재무 결과를 발표하고, 이어서 동부시간 기준 오전 8시에 컨퍼런스 콜과 라이브 웹캐스트를 진행할 예정입니다.
투자자 및 관심 있는 분들은 사전에 등록하여 지역 또는 무료 전화번호를 받을 수 있습니다. 웹캐스트는 Teva 투자자 관계 웹사이트를 통해 시청할 수 있으며, 통화 종료 후 24시간 이내에 다시보기 서비스도 제공됩니다.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 30 juillet 2025. La société publiera ses résultats financiers à 7h00 ET, suivis d'une conférence téléphonique et d'une diffusion en direct à 8h00 ET.
Les investisseurs et parties intéressées peuvent participer en s'inscrivant à l'avance pour obtenir des numéros locaux ou gratuits. La diffusion en direct sera accessible via le site web des relations investisseurs de Teva, avec un replay disponible dans les 24 heures suivant l'appel.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 30. Juli 2025 geplant. Das Unternehmen wird seine Finanzergebnisse um 7:00 Uhr ET veröffentlichen, gefolgt von einer Telefonkonferenz und einem Live-Webcast um 8:00 Uhr ET.
Investoren und Interessierte können durch vorherige Registrierung teilnehmen, um lokale oder gebührenfreie Telefonnummern zu erhalten. Der Webcast ist über die Investor-Relations-Website von Teva zugänglich, mit einer Wiederholung innerhalb von 24 Stunden nach dem Anruf.
- None.
- None.
TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients’ needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors”. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquires
TevaIR@Tevapharm.com
FAQ
When will Teva (TEVA) release its Q2 2025 financial results?
How can investors access Teva's Q2 2025 earnings conference call?
What time is Teva's Q2 2025 earnings conference call?
Where can I find the replay of Teva's Q2 2025 earnings call?
